Sugi Predict

Sugi Predict / Compounds / SCHEMBL21722644

SCHEMBL21722644

SCHEMBL21722644

Cc1cc2c(c([N+](=O)[O-])c1Br)CCC2

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 4/20 0.49
▸ GRIN3B O60391 4/20 0.49
▸ GRIN1 Q05586 4/20 0.49
▸ GRIN2A Q12879 4/20 0.49
▸ GRIN2B Q13224 4/20 0.49
▸ GRIN2C Q14957 4/20 0.49
▸ GRIN3A Q8TCU5 4/20 0.49
▸ CYP1A2 P05177 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.36
▸ TDP1 Q9NUW8 3/20 0.36
▸ MAPT P10636 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ NLRP3 Q96P20 3/20 0.32
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30951186 0.82 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29284973 0.82 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23012514 0.82 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29573587 0.80 GRIN2D (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21722756 0.80 GRIN2D (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21646772 0.80 GRIN2D (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21962247 0.78 GRIN2D (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21729510 0.78 GRIN2D (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30951204 0.77 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29284837 0.77 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338255-B2 Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2025-06-24 — — US disclosed
US-12187702-B2 Sulfonamideurea compounds INFLAZOME LIMITED (IE) 2025-01-07 — — US disclosed
CN-119110803-A Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity 唯久生物技术(苏州)有限公司 2024-12-10 — — CN disclosed
US-20240400561-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-12-05 — — US disclosed
CN-118251393-A Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity 唯久生物技术(苏州)有限公司 2024-06-25 — — CN disclosed
US-11976054-B2 Amide derivative and preparation method therefore and use thereof in medicine CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) 2024-05-07 — — US disclosed
WO-2023230002-A1 NLRP3 INFLAMMASOME INHIBITORS VenatoRx Pharmaceuticals, Inc. (US) 2023-11-30 — — WO disclosed
CN-117105890-A Amide derivative, preparation method thereof and application thereof in medicine 成都百裕制药股份有限公司 2023-11-24 — — CN disclosed
US-20230279026-A1 NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2023-09-07 — — US disclosed
US-20230279026-A1 NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2023-09-07 — — US disclosed
US-20210163412-A1 NOVEL SULFONEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2021-06-03 — — US disclosed
CN-112888675-A Novel sulfonylurea compound 英夫拉索姆有限公司 2021-06-01 — — CN disclosed
CN-112851607-A Amide derivative, preparation method and medical application thereof 成都百裕制药股份有限公司 2021-05-28 — — CN disclosed
WO-2021093820-A1 AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-05-20 — — WO disclosed
CN-112789264-A Novel sulfonylurea compound 英夫拉索姆有限公司 2021-05-11 — — CN disclosed
CN-112672995-A Novel sulfonamide urea compounds 英夫拉索姆有限公司 2021-04-16 — — CN disclosed
CN-112533913-A Novel compounds 英夫拉索姆有限公司 2021-03-19 — — CN disclosed
EP-3788041-A1 NOVEL COMPOUNDS Inflazome Limited (IE) 2021-03-10 — — EP disclosed
WO-2021032591-A1 MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2021-02-25 — — WO disclosed
WO-2020035465-A1 NOVEL SULFONEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2020-02-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400561-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 GRIN2D 3630/4885GRIN3B 3814/4885GRIN1 1104/4885
US-11976054-B2 Amide derivative and preparation method therefore and use thereof in medicine NLRP3, NLRP1, PYCARD GRIN2D 1124/4885GRIN3B 1491/4885GRIN1 1345/4885
US-12187702-B2 Sulfonamideurea compounds NLRP3, NOD1, NLRP1 GRIN2D 3798/4885GRIN3B 3330/4885GRIN1 2902/4885
US-20230279026-A1 NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 GRIN2D 3088/4885GRIN3B 3775/4885GRIN1 921/4885
US-12338255-B2 Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity IL1B, IL1A, IL18 GRIN2D 2963/4885GRIN3B 3616/4885GRIN1 841/4885
US-20210163412-A1 NOVEL SULFONEUREA COMPOUNDS NLRP3, NLRP1, PYCARD GRIN2D 3931/4885GRIN3B 4322/4885GRIN1 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.